SAB Biotherapeutics, Inc. (NASDAQ:SABS) Receives Average Recommendation of “Moderate Buy” from Brokerages

SAB Biotherapeutics, Inc. (NASDAQ:SABS) has earned an average recommendation of “Moderate Buy” from the five ratings firms that are currently covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, three have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month price objective among analysts that have covered the stock in the last year is $9.3333.

Several equities analysts have recently issued reports on the stock. Wall Street Zen raised shares of SAB Biotherapeutics to a “sell” rating in a research note on Saturday, September 20th. HC Wainwright lowered their price objective on shares of SAB Biotherapeutics from $10.00 to $9.00 and set a “buy” rating on the stock in a research note on Tuesday, July 22nd. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of SAB Biotherapeutics in a research note on Tuesday. Leerink Partnrs raised shares of SAB Biotherapeutics to a “strong-buy” rating in a research note on Wednesday, September 17th. Finally, Chardan Capital reissued a “buy” rating and issued a $12.00 target price on shares of SAB Biotherapeutics in a research report on Friday, September 19th.

SAB Biotherapeutics Stock Down 0.4%

SABS stock opened at $2.30 on Wednesday. SAB Biotherapeutics has a 52 week low of $1.00 and a 52 week high of $6.60. The company has a market capitalization of $23.95 million, a price-to-earnings ratio of -0.58 and a beta of 0.54. The firm’s 50-day moving average is $2.19 and its two-hundred day moving average is $1.96. The company has a current ratio of 0.87, a quick ratio of 0.87 and a debt-to-equity ratio of 0.27.

SAB Biotherapeutics (NASDAQ:SABS) last announced its quarterly earnings data on Thursday, August 7th. The company reported ($1.09) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.82) by ($0.27). On average, analysts forecast that SAB Biotherapeutics will post -3.69 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in SAB Biotherapeutics stock. HB Wealth Management LLC lifted its position in SAB Biotherapeutics, Inc. (NASDAQ:SABS) by 10.9% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 263,200 shares of the company’s stock after acquiring an additional 25,800 shares during the period. HB Wealth Management LLC owned about 2.83% of SAB Biotherapeutics worth $358,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 7.82% of the company’s stock.

About SAB Biotherapeutics

SAB Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases.